Oligonucleotide-based nano carrier for co-delivering drug and gene and preparation method of nano carrier

An oligonucleotide and nanocarrier technology is applied in the field of nanocarriers and preparation of co-delivery drugs and genes based on oligonucleotides, which can solve the problems of low drug loading and improve the anti-tumor effect. Reduce toxic side effects and improve accumulation effect

Active Publication Date: 2015-01-07
SHANDONG UNIV
View PDF4 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the simple aptamer loading drug has a low drug loading capacity. In order to improv

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligonucleotide-based nano carrier for co-delivering drug and gene and preparation method of nano carrier
  • Oligonucleotide-based nano carrier for co-delivering drug and gene and preparation method of nano carrier
  • Oligonucleotide-based nano carrier for co-delivering drug and gene and preparation method of nano carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] The oligonucleotides used in this example are formed by the annealing of two complementary single-stranded nucleotides consisting of (CGA) repeat sequences (CGA) 7 , strand 1: 5'-CGACGACGACGACGACGACGA-3'; strand 2: 5'-TCGTCGTCGTCGTCGTCGTCG-3', as shown in SEQ ID NO.1, SEQ ID NO.2; siRNA specifically targets vascular endothelial growth factor (VEGF ) siRNA, the sequence is: sense strand 5'-ACAUCACCAUGCAGAUUAUdTdT-3'; antisense strand 5'-dTdTUGUAGUGGUACGUCUAAUA-3' as shown in SEQ ID NO.3 and SEQ ID NO.4.

[0037] Mix 100 μL of doxorubicin aqueous solution with a concentration of 50 μM and 120 μL of an oligonucleotide solution with a concentration of 10 μM, vortex for 20 s, and after standing at room temperature for 5 min, add specific For siRNA targeting VEGF, vortex for 20s, and mix well to obtain a mixed solution.

[0038] Add 200 μL of the above-prepared mixed solution drop by drop into the polyetherimide (PEI) solution with a volume of 200 μL and a concentration of 8...

Embodiment 2

[0041] The aptamer used in this example is aptamer A10, the sequence is: 5'-GGGAGGACGAUGCGGAUCAGC CAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGGC-3', as shown in SEQ ID NO.5; siRNA is siRNA specifically targeting VEGF, and the sequence is as shown in SEQ ID NO.3, shown in SEQ ID NO.4.

[0042] Mix 100 μL of doxorubicin aqueous solution with a concentration of 20 μM and 80 μL of aptamer A10 with a concentration of 10 μM, vortex for 20 s, and after standing at room temperature for 5 min, add a specific target with a mass ratio of 1:2 to doxorubicin. Add siRNA to VEGF, vortex for 20s, mix well, take 200μL of the mixed solution drop by drop into the PLL solution with a concentration of 200μg / mL and a volume of 150μL under the vortex condition, continue to vortex for 20s, and incubate at room temperature for 30min. A polycation complex co-loaded with doxorubicin and siRNA. The polycation complex co-loaded with doxorubicin and siRNA prepared above has a particle size of 107.9 nm, a polydispersi...

Embodiment 3

[0045] The oligonucleotides used in this example are formed by the annealing of two complementary single-stranded nucleotides consisting of (CGA) repeat sequences (CGA) 5 , strand 1: 5'-CGACGACGACGACGA-3'; strand 2: 5'-TCGTCGTCGTCGTCG-3', the sequence is shown in SEQ ID NO.6 and SEQ ID NO.7, and siRNA specifically targets multidrug resistance genes The sequence of siRNA for MDR-1 is: positive sense strand: 5'-GGAUAUUAGGACCAUAAAUdTdT-3', antisense strand 5'-AUUUAUGGUCCUAAUAUCCdTdT-3', as shown in SEQ ID NO.8 and SEQ ID NO.9.

[0046] Mix 100 μL daunorubicin aqueous solution with a concentration of 40 μM and 100 μL oligonucleotide solution with a concentration of 10 μM, vortex for 20 s, and after standing at room temperature for 5 min, add specific For siRNA targeting multidrug resistance gene 1 (MDR-1), vortex for 20s, mix well, add 200 μL of the above mixed solution drop by drop into the PPI solution with a concentration of 100 μg / mL and a volume of 300 μL under vortex conditi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses an oligonucleotide-based nano carrier for co-delivering drug and gene and a preparation method of the nano carrier. The method comprises the following steps: 1, mixing an oligonucleotide solution with a drug solution, standing at room temperature for 1-100 minutes, and then mixing with siRNA to obtain a mixed solution; 2, adding a cationic polymer solution to the mixed solution obtained in the step 1), standing and incubating at room temperature for 1-100 minutes, so as to obtain a polycation compound co-loading drug and gene; 3, adding an anionic polymer solution to the polycation compound obtained in the step 2), standing and incubating at room temperature for 1-100 minutes, so as to obtain an oligonucleotide-based nano carrier for co-delivering drug and gene. The preparation process of the oligonucleotide-based nano carrier for co-delivering drug and gene is simple and feasible and the oligonucleotide-based nano carrier for co-delivering drug and gene can be applied to treatment of a plurality of cancers such as liver cancer, lung cancer, breast cancer and ovarian cancer.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a co-delivery drug delivery system, in particular to a nano-carrier and a preparation method for co-delivering drugs and genes based on oligonucleotides. Background technique [0002] Cancer is a common and frequently-occurring disease that seriously threatens human health. The global mortality rate is as high as 13%, and the incidence rate is increasing year by year. Therefore, the task of cancer prevention and treatment is very arduous. There are three main methods of cancer treatment: drug therapy, gene therapy and radiation therapy. Among them, drug therapy, also known as chemotherapy, is currently a widely used treatment method in clinical practice. Most of the antitumor drugs used in it can directly and quickly kill tumor cells. However, the non-specificity of antitumor drugs also enhances the effects of chemotherapy. Nausea, vomiting, hair loss and other toxic sid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K47/36A61K47/34A61K47/32A61K47/18A61K45/00A61K31/704A61P35/00
Inventor 张娜刘婷先刘永军刘春喜王明芳
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap